SPOTLIGHT: Depomed reports trial success


Depomed says that a mid-stage trial of the extended release version of gabapentin demonstrated that the therapy significantly reduced the severity and frequency of the hot flashes compared to placebo. Release

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.